Skip to main content

Advertisement

Table 2 Immunogenicity to HPV Vaccine

From: Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years

HPV genotype % Seropositivity * 95% CI § cLIA GMT mMu/ml † (95% CI)
Anti-HPV 6 94.4 (72.7, 99.9) 427.0 (203.4, 903.4)
Anti-HPV 11 100 (81.5, 100) 596.7 (303.6, 1173.2)
Anti-HPV 16 100 (81.5, 100) 2263.2 (1019.3, 5024.8)
Anti-HPV 18 94.4 (72.7, 99.9) 331.9 (159.8, 689.2)
  1. *Seropositivity and anti-HPV values were determined in the 16 patients who completed the vaccine HPV series and had both pre- and post-vaccination serum available for HPV antibody measurement.
  2. § CI = Confidence Interval.
  3. †cLIA GMT mMu = Competitive Luminex immunoassay, Geometric Mean Titers measured in milli-Merck units.